Custom service

De novo Peptide Design

Design peptide sequences de novo against a functional objective

Turnaround: 4–8 weeksTypical scale: 0.1 mg – 10 g per sequenceChemistry options: structure- and AI-informed sequence design; stability and solubility optimization; design-build-test iteration

The service is built around structure- and AI-informed sequence design. Depending on the molecule we may move to stability and solubility optimization or design-build-test iteration to improve stability, loading or yield, and every batch is released with design dossier plus synthesized candidates.

Because De novo Peptide Design projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

Binders for targets without known motifs

Novel scaffolds for research programmes

Designs without a testable assay or structure

Sequences where a recombinant expression route is objectively cheaper and faster

Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.

Service Highlights

  • Structure- and AI-informed sequence design as the default route, with stability and solubility optimization held as a proven fallback
  • Design-build-test iteration worked into the design where the application requires it
  • Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
  • Analytical confirmation of every intermediate before the final release
  • Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
  • Design dossier plus synthesized candidates delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sequence analysis

    De novo Peptide Design is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.

  2. Route selection

    Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.

  3. Assembly

    The chain is built with structure- and AI-informed sequence design applied where the sequence demands it, with double-coupling at hazard sites.

  4. Cleavage & crude QC

    Crude material is characterized so purification targets are set on data, not hope.

  5. Purification

    RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.

  6. Release

    Design dossier plus synthesized candidates is documented with the full analytical package and released.

Specifications & timeline

Turnaround
4–8 weeks
Typical scale
0.1 mg – 10 g per sequence
Chemistry options
structure- and AI-informed sequence design; stability and solubility optimization; design-build-test iteration
Deliverable
Design dossier plus synthesized candidates
QC package
HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
Shipping
Ambient with desiccant; blue ice for modified or sensitive peptides

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.